Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019 : an international, multicenter, double-blind, randomized controlled trial
© 2023. The Author(s)..
BACKGROUND: In a randomized trial, Lianhuaqingwen (LHQW) capsule was effective for accelerating symptom recovery among patients with coronavirus disease 2019 (COVID-19). However, the lack of blinding and limited sample sizes decreased the level of clinical evidence.
OBJECTIVES: To evaluate the efficacy and safety of LHQW capsule in adults with mild-to-moderate COVID-19.
METHODS: We conducted a double-blind randomized controlled trial in adults with mild-to-moderate COVID-19 (17 sites from China, Thailand, Philippine and Vietnam). Patients received standard-of-care alone or plus LHQW capsules (4 capsules, thrice daily) for 14 days. The primary endpoint was the median time to sustained clinical improvement or resolution of nine major symptoms.
RESULTS: The full-analysis set consisted of 410 patients in LHQW capsules and 405 in placebo group. LHQW significantly shortened the primary endpoint in the full-analysis set (4.0 vs. 6.7 days, hazards ratio: 1.63, 95% confidence interval: 1.39-1.90). LHQW capsules shortened the median time to sustained clinical improvement or resolution of stuffy or runny nose (2.8 vs. 3.7 days), sore throat (2.0 vs. 2.6 days), cough (3.2 vs. 4.9 days), feeling hot or feverish (1.0 vs. 1.3 days), low energy or tiredness (1.3 vs. 1.9 days), and myalgia (1.5 vs. 2.0 days). The duration to sustained clinical improvement or resolution of shortness of breath, headache, and chills or shivering did not differ significantly between the two groups. Safety was comparable between the two groups. No serious adverse events were reported.
INTERPRETATION: LHQW capsules promote recovery of mild-to-moderate COVID-19 via accelerating symptom resolution and were well tolerated. Trial registration ChiCTR2200056727.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:20 |
|---|---|
| Enthalten in: |
Virology journal - 20(2023), 1 vom: 28. Nov., Seite 277 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Zheng, Jin-Ping [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Coronavirus disease 2019 |
|---|
| Anmerkungen: |
Date Completed 01.12.2023 Date Revised 01.12.2023 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12985-023-02144-6 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM365086827 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM365086827 | ||
| 003 | DE-627 | ||
| 005 | 20231226100927.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12985-023-02144-6 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1216.xml |
| 035 | |a (DE-627)NLM365086827 | ||
| 035 | |a (NLM)38017515 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Zheng, Jin-Ping |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Effects of Lianhuaqingwen Capsules in adults with mild-to-moderate coronavirus disease 2019 |b an international, multicenter, double-blind, randomized controlled trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 01.12.2023 | ||
| 500 | |a Date Revised 01.12.2023 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023. The Author(s). | ||
| 520 | |a BACKGROUND: In a randomized trial, Lianhuaqingwen (LHQW) capsule was effective for accelerating symptom recovery among patients with coronavirus disease 2019 (COVID-19). However, the lack of blinding and limited sample sizes decreased the level of clinical evidence | ||
| 520 | |a OBJECTIVES: To evaluate the efficacy and safety of LHQW capsule in adults with mild-to-moderate COVID-19 | ||
| 520 | |a METHODS: We conducted a double-blind randomized controlled trial in adults with mild-to-moderate COVID-19 (17 sites from China, Thailand, Philippine and Vietnam). Patients received standard-of-care alone or plus LHQW capsules (4 capsules, thrice daily) for 14 days. The primary endpoint was the median time to sustained clinical improvement or resolution of nine major symptoms | ||
| 520 | |a RESULTS: The full-analysis set consisted of 410 patients in LHQW capsules and 405 in placebo group. LHQW significantly shortened the primary endpoint in the full-analysis set (4.0 vs. 6.7 days, hazards ratio: 1.63, 95% confidence interval: 1.39-1.90). LHQW capsules shortened the median time to sustained clinical improvement or resolution of stuffy or runny nose (2.8 vs. 3.7 days), sore throat (2.0 vs. 2.6 days), cough (3.2 vs. 4.9 days), feeling hot or feverish (1.0 vs. 1.3 days), low energy or tiredness (1.3 vs. 1.9 days), and myalgia (1.5 vs. 2.0 days). The duration to sustained clinical improvement or resolution of shortness of breath, headache, and chills or shivering did not differ significantly between the two groups. Safety was comparable between the two groups. No serious adverse events were reported | ||
| 520 | |a INTERPRETATION: LHQW capsules promote recovery of mild-to-moderate COVID-19 via accelerating symptom resolution and were well tolerated. Trial registration ChiCTR2200056727 | ||
| 650 | 4 | |a Randomized Controlled Trial | |
| 650 | 4 | |a Multicenter Study | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Coronavirus disease 2019 | |
| 650 | 4 | |a Inflammation | |
| 650 | 4 | |a Lianhuaqingwen Capsule | |
| 650 | 4 | |a Omicron | |
| 650 | 4 | |a Symptom resolution | |
| 650 | 7 | |a Drugs, Chinese Herbal |2 NLM | |
| 650 | 7 | |a lianhuaqingwen |2 NLM | |
| 700 | 1 | |a Ling, Yun |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Liang-Shuang |e verfasserin |4 aut | |
| 700 | 1 | |a Mootsikapun, Piroon |e verfasserin |4 aut | |
| 700 | 1 | |a Lu, Hong-Zhou |e verfasserin |4 aut | |
| 700 | 1 | |a Chayakulkeeree, Methee |e verfasserin |4 aut | |
| 700 | 1 | |a Zhang, Li-Xiu |e verfasserin |4 aut | |
| 700 | 1 | |a Arttawejkul, Pureepat |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, Feng-Yu |e verfasserin |4 aut | |
| 700 | 1 | |a Truong, Thi Ngoc Lan |e verfasserin |4 aut | |
| 700 | 1 | |a Perez, Roxan A |e verfasserin |4 aut | |
| 700 | 1 | |a Gu, Xing |e verfasserin |4 aut | |
| 700 | 1 | |a Sun, Hui-Min |e verfasserin |4 aut | |
| 700 | 1 | |a Jiang, Jian-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Ren-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Ding, Zhen |e verfasserin |4 aut | |
| 700 | 1 | |a Zhan, Yang-Qing |e verfasserin |4 aut | |
| 700 | 1 | |a Yang, Zi-Feng |e verfasserin |4 aut | |
| 700 | 1 | |a Guan, Wei-Jie |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, Nan-Shan |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Virology journal |d 2004 |g 20(2023), 1 vom: 28. Nov., Seite 277 |w (DE-627)NLM151772509 |x 1743-422X |7 nnns |
| 773 | 1 | 8 | |g volume:20 |g year:2023 |g number:1 |g day:28 |g month:11 |g pages:277 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12985-023-02144-6 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 20 |j 2023 |e 1 |b 28 |c 11 |h 277 | ||